Associated tags: HKEX, Attention, Pharmaceutical industry, Hospital, Hyperlipidemia, Blood pressure, Diabetes, Obesity, Safety, Hypoglycemia, ClinicalTrials.gov, Ophthalmology, Metformin, Liver disease, Patient, GCGR, Moyamoya disease, Trial of the century, Glycated hemoglobin, Gout
Diagnosis,
Health,
Regeneration,
Learning,
Glycated hemoglobin,
Menin,
C-peptide,
Insulin,
Diabetes,
AUC,
Patient,
Fasting,
MD,
Metformin,
Person,
Cancer,
Safety,
A1C,
DSM-IV codes,
Pharmaceutical industry REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced initial response data from the first two type 1 diabetes patients treated with BMF-219 in the ongoing Phase II study (COVALENT-112).
Key Points:
- “We are very excited to announce the initial response data from the first two type 1 diabetes patients enrolled in the COVALENT-112 study.
- Both patients showed improvement in measures of beta-cell function after only 4 weeks of dosing with BMF-219.
- The trial includes an open label portion for adults with type 1 diabetes up to 15 years since diagnosis.
- It has been exciting to participate in this study and explore this new pathway for the benefit of our patients.
Retrieved on:
Tuesday, January 10, 2023
HKEX,
Liver disease,
Food and Drug Administration Safety and Innovation Act,
Type 2 diabetes,
Drug,
SGLT2,
Gout,
Glycated hemoglobin,
Trial of the century,
Moyamoya disease,
GCGR,
Patient,
Metformin,
Attention,
Ophthalmology,
ClinicalTrials.gov,
Hypoglycemia,
Safety,
Obesity,
Diabetes,
Blood pressure,
Hyperlipidemia,
Hospital,
Pharmaceutical industry,
Beijing Hospital of Traditional Chinese Medicine In a phase 2 clinical study of mazdutide in Chinese patients with type 2 diabetes (ClinicalTrials.gov, NCT04965506), mazdutide was well tolerated and the overall safety profile was similar to other GLP-1 class drugs.
Key Points:
- In a phase 2 clinical study of mazdutide in Chinese patients with type 2 diabetes (ClinicalTrials.gov, NCT04965506), mazdutide was well tolerated and the overall safety profile was similar to other GLP-1 class drugs.
- In the study, mazdutide reduced blood pressure, blood lipids and liver enzyme levels, offering metabolic benefits to subjects.
- The phase 2 clinical study in Chinese patients with type 2 diabetes showed significant glucose-lowering efficacy of mazdutide, and it also showed the potential superiority of mazdutide to dulaglutide in weight-loss efficacy.
- As a promising example of GLP-1 dual-target drugs, mazdutide has been extensively researched and developed in Chinese patients with type 2 diabetes.
Retrieved on:
Wednesday, April 22, 2020
Evotec has built a unique platform for iPSC-based drug discovery and cell therapy covering the generation of iPS cell lines, up to cell manufacturing of various cell types for drug screening as well as GMP production of clinical material for cell therapies.
Key Points:
- Evotec has built a unique platform for iPSC-based drug discovery and cell therapy covering the generation of iPS cell lines, up to cell manufacturing of various cell types for drug screening as well as GMP production of clinical material for cell therapies.
- Evotec will continue the development of the beta cell programme on its own within its EVT Innovate initiative "QRbeta Therapeutics".
- Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Evotec and Sanofi have developed the beta cell replacement therapy programme since 2015 in a highly productive partnership.
- Furthermore, beta cell replacement therapy also has the potential to prevent or reverse the decline in beta cell function in type 2 diabetes.
